NVO - Novo Nordisk's 'Miracle' Weight Loss Drug Ozempic Linked To 48% Lower Risk Of Dementia Study Finds | Benzinga
Novo Nordisk A/S. (NYSE:NVO) has found that its “miracle” weight loss drug used for diabetes, Ozempic, is linked to a significant reduction in the risk of dementia and other cognitive issues.
What Happened: A study conducted at the University of Oxford revealed that patients who used Ozempic had a 48% lower risk of dementia compared to those who used an older drug, sitagliptin. The study also showed a lower risk of cognitive deficits in comparison to patients who had taken either sitagliptin or glipizide, another older medicine, reported Bloomberg on Friday.
Patients on Ozempic also had a 28% lower risk of smoking than those who were on glipizide. These findings have raised expectations about the potential ancillary benefits of the drug.
The study is part of a series of trials that have shown potential benefits beyond diabetes control and weight loss for semaglutide, the main ingredient in both Ozempic and Novo’s obesity medicine Wegovy.
Most of the other benefits are linked to weight loss, but scientists are ...